Medios Technologies
AcquiredEntrepreneur First '17Singapore, SG · Founded 2017 · 1 known investors
Medios Technologies built deep learning software that analyzes retinal images to identify signs of diabetic retinopathy within seconds. The screening tool was designed for primary care clinicians in settings with few ophthalmologists, allowing eye checks to be folded into routine visits. The company was acquired by Remidio in 2019.
Also known as Medios
Founders & leadership
Medios Technologies was founded in 2017 by Bhargav Sosale and Florian Savoy.
Investors · 1
Company profile
researched Aug 2026Medios Technologies is a Singapore-based developer of deep learning software that analyses retinal images to detect diabetic retinopathy during routine diabetes check-ups. A retinal image is captured and processed by the software, which returns an almost immediate diagnostic output; at minimum the tool helps general practitioners triage which patients require referral to an ophthalmology specialist [0].
The company was co-founded by Florian Savoy, a computer vision researcher who moved from academia into entrepreneurship, together with Bhargav Sosale, who serves as CEO. Medios subsequently became the AI arm of Remidio, an ophthalmic devices startup, with its algorithms integrated into Remidio's low-cost, portable fundus-on-phone retinal cameras used by clinicians and nurses in primary care settings [1].
Beyond diabetic retinopathy, the team has been building a multi-model AI solution for retinopathy of prematurity, a treatable cause of childhood blindness in preterm infants. Medios also maintains a medical director on staff and runs six-month apprenticeships through SGInnovate's Summation Programme, mentored by Savoy [1].
Founding story
Co-founder Florian Savoy had spent more than five years in computer vision research and wanted to move out of academia into work with more practical impact. Encouraged by a local investor programme supporting technology entrepreneurs, he co-founded Medios Technologies with fellow entrepreneur Bhargav Sosale and developed a deep learning solution enabling any doctor to rapidly detect diabetic retinopathy [1].
Business model
Medios develops AI diagnostic software rather than selling standalone clinical services. Following its combination with Remidio, the AI is embedded in Remidio's low-cost, portable retinal cameras, so the software reaches clinicians as part of a device offering [1]. The sources do not describe pricing, contract structures or channel economics.
Not stated in the available sources.
Traction
The technology is deployed for screening diabetes patients at primary care centres and is being commercialised in India, Europe and Singapore as part of Remidio's retinal camera products [1]. No customer counts, revenue or volume figures appear in the sources.
Latest developments
As of the SGInnovate interview, Medios operates as the AI arm of Remidio, its diabetic retinopathy solution is being commercialised in India, Europe and Singapore, and the team is building several AI models toward a full solution for screening retinopathy of prematurity. Savoy mentors apprentices through SGInnovate's Summation Programme, and at least one former intern converted to a permanent employee [1].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The sources position Medios as the AI component of Remidio's ophthalmic device business rather than as a standalone vendor, and do not provide market share, revenue or competitive ranking data. A third-party venture database profile of the company lists no Alpha Score or financial figures [0].
The sources emphasise the company's investment in dataset curation — examining how disease presents in images and correcting labelling flaws before model training — as a prerequisite to workable clinical AI, and its distribution via low-cost portable retinal cameras that allow screening to occur at primary care centres rather than specialist clinics [1].
Technology
Deep learning models trained on thousands of retinal images to identify signs of diabetic retinopathy from a single eye image and return a near-immediate result [0][1]. The team describes heavy emphasis on data preparation — understanding how the disease presents in images and identifying labelling flaws — before model training, and is developing multiple models for a retinopathy of prematurity screening solution [1].
Go-to-market
The AI is distributed through Remidio's portable retinal cameras and deployed at primary care centres so that diabetes patients can be screened during standard check-ups [1]. The sources do not describe sales organisation or partner channels in further detail.
General practitioners and primary care clinicians treating diabetes patients, including nurses operating portable retinal cameras, particularly where ophthalmology specialists are limited; the tool also supports referral triage to specialists [0][1].
Geography
Headquartered in Singapore, with the AI-enabled retinal screening solution being commercialised in India, Europe and Singapore; a nurse in India is cited as an example user of the Remidio device running Medios AI [1].
History
Florian Savoy, who had spent over five years researching computer vision, co-founded the company with Bhargav Sosale with the encouragement of a local investor programme supporting technology entrepreneurs; Savoy dates the founding to 2018 (internal records date it to 2017) [1]. The team built a deep learning system for rapid diabetic retinopathy detection. The company subsequently became the AI arm of ophthalmic device maker Remidio, and by roughly five years after founding its technology was being commercialised in India, Europe and Singapore, while the team was also developing AI models for retinopathy of prematurity [1].
Risks & controversies
No risks or controversies about the company are reported in the available sources. Source records give conflicting founding years: internal data indicates 2017 while the co-founder's interview states 2018 [1].
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsCTO and co-founder Florian Savoy mentors six-month apprentices at Medios through SGInnovate's Summation Programme, with apprentices working on components of Medios' AI solutions.
Savoy describes an in-progress AI-based solution, composed of several AI models, to screen for retinopathy of prematurity, a leading cause of avoidable childhood blindness.
Co-founder Florian Savoy states that Medios is now the AI arm of Remidio, an ophthalmic devices startup, with Medios' AI integrated into Remidio's low-cost portable retinal cameras. The source does not state a transaction date or amount.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Medios Technologies Company Profile: Funding, Investors & Partnershipshealthtechalpha.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medios Technologies do?
- Singapore deep learning company whose retinal-image AI detects diabetic retinopathy in primary care; now Remidio's AI arm.
- Who founded Medios Technologies?
- Medios Technologies was founded by Bhargav Sosale, Florian Savoy in 2017.
- Who are Medios Technologies's investors?
- Medios Technologies's investors include Entrepreneur First.
- Where is Medios Technologies headquartered?
- Medios Technologies is headquartered in Singapore, SG.